健康元药业集团 注射用醋酸亮丙瑞林微球通过一致性评价的公告 证券代码：600380 证券简称：健康元 公告编号：临 2024-108 健康元药业集团股份有限公司 关于注射用醋酸亮丙瑞林微球通过一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，健康元药业集团股份有限公司（以下简称：本公司）控股子公司丽珠医 药集团股份有限公司（以下简称：丽珠集团）的控股子公司上海丽珠制药有限公司 收到国家药品监督管理局核准签发的《药品补充申请批准通知书》（证书编号： 2024B04743），上海丽珠制药有限公司生产的注射用醋酸亮丙瑞林微球通过注射剂 仿制药质量和疗效一致性评价。现将相关情况公告如下： 一、药品基本情况 药品名称：注射用醋酸亮丙瑞林微球 药品注册标准编号：YBH24682024 申请内容：仿制药质量和疗效一致性评价 上市许可持有人、生产企业：上海丽珠制药有限公司 审批结论：根据《中华人民共和国药品管理法》、《国务院关于改革药品医疗 器械审评审批制度的意见》（国发〔2015〕44 号）和《关于仿制药质量和疗效一致 ...

证券代码：600380 证券简称：健康元 公告编号：临 2024-106 健康元药业集团股份有限公司 关于提供担保进展情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 ●2024 年 9 月，健康元药业集团股份有限公司（以下简称：本公司）与南洋商业 银行（中国）有限公司深圳分行（以下简称：南洋商业银行）签署担保协议，被担保人 分别为深圳市海滨制药有限公司（以下简称：海滨制药）和焦作健康元生物制品有限公 司（以下简称：焦作健康元），担保金额分别为人民币 15,000.00 万元和人民币 20,000.00 万元； 健康元药业集团 关于提供担保进展情况的公告 ●被担保人均为本公司全资子公司，不存在关联担保； ●本次担保是否有反担保：否； ●对外担保逾期的累计数量：无。 一、担保情况概述 （一）本次担保事项履行的内部决策程序 2024年4月2日，本公司召开八届董事会三十八次会议，审议并通过《关于本公司授 信融资及为下属子公司等提供融资担保的议案》，同意本公司向国家开发银行等银行申 请最高不超过人民币共计263 ...

健康元药业集团 股票期权自主行权结果公告 证券代码：600380 证券简称：健康元 公告编号：临 2024-104 健康元药业集团股份有限公司 关于公司 2022 年股票期权激励计划 2024 年第三季度自主行权结果 暨股份上市公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●本次行权股票数量：健康元药业集团股份有限公司（以下简称：公司）2022 年股 票期权激励计划首次授予股票期权第一个行权期可行权股票期权数量为 1,883.20 万份， 行权有效期为 2023 年 9 月 5 日至 2024 年 9 月 4 日。2024 年第三季度股票期权激励对象 行权且完成股份过户登记的数量为 181,083 股。 ●本次行权股票的上市流通时间：公司2022年股票期权激励计划采取自主行权方式， 行权所得股票可于行权日（T日）后的第二个交易日（T+2）日上市交易。 一、 本次股票期权行权的决策程序及相关信息披露 1、2022年8月10日，公司召开八届董事会十五次会议，审议并通过《关于公司<2022 年股票期权激励计划（ ...

健康元药业集团 委托贷款进展公告 证券代码：600380 证券简称：健康元 公告编号：临 2024-102 健康元药业集团股份有限公司 关于向控股子公司焦作健风提供委托贷款的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 委托贷款概述 健康元药业集团股份有限公司（以下简称：本公司）于2024年4月25日召开八届 董事会三十九次会议，审议并通过《关于本公司向控股子公司焦作健风提供委托贷 款的议案》，同意本公司向控股子公司焦作健风生物科技有限公司（以下简称：焦作 健风）因前期项目建设及流动资金需求提供期限五年，总金额为人民币10,000万元的 委托贷款。贷款利率为浮动利率，根据中国人民银行公布的一年期贷款市场报价利 率(LPR)+65BP。同时本次委托贷款由焦作健风另外股东风火轮(上海)生物科技有限 公司以其所持有的焦作健风股权作为担保。 具体内容详见公司于2024年4月26日披露的《健康元药业集团股份有限公司关于 本公司向控股子公司焦作健风提供委托贷款的公告》（临2024-038）。 二、 委托贷款进展情况 20 ...

健康元药业集团股份有限公司（以下简称：公司）于 2024 年 09 月 20 日（星期五）下 午 15:00-16:30 在上海证券交易所上证路演中心（网址：http://roadshow.sseinfo.com/），以 视频与网络文字互动方式召开了 2024 年半年度业绩说明会，针对公司 2024 年半年度的经 营成果及财务指标等具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内就 投资者普遍关注的问题进行现场回复，现就有关情况公告如下： 一、本次说明会召开情况 2024 年 09 月 20 日（星期五）下午 15:00-16:30，公司在上海证券交易所上证路演中心 召开 2024 年半年度业绩说明会，公司董事长朱保国先生，董事、总裁林楠棋先生，董事、 副总裁兼财务负责人邱庆丰先生，独立董事霍静女士、彭娟女士，副总裁兼董事会秘书赵 凤光先生出席本次说明会，就 2024 年半年度的经营成果及财务指标等具体情况与投资者进 行互动交流，并回复投资者提出的相关问题。 二、本次说明会投资者提出的主要问题及公司答复情况 本次说明会现场投资者提出的主要问题及答复整理如下： 健康元药业集团 关于2024年半年度业绩 ...

Financial Performance - The company reported a main business revenue of 8.173 billion RMB, representing a year-on-year increase of 49.85%[10]. - The company's operating revenue for the first half of 2024 was CNY 8,234,634,099.45, a decrease of 5.56% compared to the same period last year[20]. - Net profit attributable to shareholders was CNY 776,424,466.87, down 4.78% year-on-year[20]. - The basic earnings per share (EPS) for the period was 1.07 RMB, while the diluted EPS was 0.88 RMB[10]. - The basic earnings per share for the first half of 2024 was CNY 0.4158, a decrease of 2.49% compared to the same period last year[21]. - The company achieved a total revenue of 12,352.7 billion CNY in the first half of 2024, a decrease of 0.9% year-on-year[35]. - The company's total comprehensive income for the first half of 2024 was approximately CNY 846.62 million, with a net profit of CNY 815.43 million[191]. - The total amount of undistributed profits was CNY 8.94 billion, indicating a significant portion of earnings retained for future growth[192]. Research and Development - The company has established a comprehensive R&D model focusing on innovative drugs and high-barrier complex formulations, with a clear product development pipeline in key areas such as respiratory, oncology, and immunology[27]. - The company continues to invest in R&D, collaborating with external research institutions to enhance its product pipeline and market position[39]. - The total R&D investment amounted to 780.81 million RMB, representing 9.48% of total revenue, with a year-on-year growth of approximately 4.66%[63][64]. - The company is focusing on high-barrier complex formulations and innovative drug development, including AI drug design and gene editing technologies[42]. - The company has multiple innovative drug projects in progress, including TG-1000 for influenza, which has been submitted for production approval[65]. Operational Risks and Compliance - The company has outlined various risks in its operations, including industry policy risk, market risk, and R&D risk, but stated that there were no significant risks impacting production and operations during the reporting period[6]. - The company emphasized its commitment to ensuring the authenticity, accuracy, and completeness of the financial report, with all board members present at the meeting[3]. - The report is unaudited, but the management has confirmed the integrity of the financial statements[4]. - The company has not faced any significant operational risks that could materially affect its business during the reporting period[6]. - The company has not reported any violations or penalties involving its directors, supervisors, or senior management during the reporting period[145]. Environmental Compliance - The company has implemented strict compliance with various environmental regulations, including the Water Pollution Prevention and Control Law[109]. - The company’s overall environmental performance indicates no instances of exceeding emission limits across various pollutants[105][106][109]. - The company has been recognized as a national green factory by the Ministry of Industry and Information Technology in 2023[119]. - The company has established a management system for financial derivatives trading to control transaction risks[85]. - The company has implemented a comprehensive waste gas treatment system, including RTO technology, to ensure stable compliance with emission standards[117]. Market Strategy and Expansion - The company is actively engaged in technology cooperation with domestic and international research institutions to enhance its strategic development goals[27]. - The company is focusing on expanding its international market presence while maintaining strong relationships with global strategic customers[58]. - The company is exploring potential mergers and acquisitions to enhance its market position and diversify its product offerings[191]. - The company is committed to improving its safety and environmental management systems to address risks associated with chemical production and increasing environmental regulations[90]. - The company plans to enhance its compliance system and increase hospital coverage and product sales to mitigate the impact of price adjustments from medical insurance payments, aiming for a "volume over price" strategy[88]. Shareholder and Governance - The company has made changes in its board of directors, including the election of a new supervisor and the appointment of a new executive vice president, to ensure effective governance and management[95]. - The company will allow independent directors of Lizhu Group to review compliance with commitments at least once a year[141]. - The company will not interfere with Lizhu Group's management activities or infringe on its interests[142]. - The company has not engaged in any share repurchase activities during the reporting period[168]. - The company approved a related party transaction with Jinchuan Electric for the procurement of steam and power, with a maximum estimated amount of RMB 300 million for 2024[147]. Financial Position - The company's total assets at the end of the reporting period were CNY 36,496,077,306.20, a slight increase of 0.38% from the previous year[20]. - The company's equity attributable to shareholders increased to CNY 14,312,142,966.13 from CNY 13,755,901,924.06, marking an increase of approximately 4.04%[179]. - The total liabilities decreased to CNY 13,382,450,171.37 from CNY 13,718,595,768.18, representing a reduction of about 2.46%[179]. - The company's cash and cash equivalents decreased to CNY 15,258,884,810.36 from CNY 15,691,888,314.83, a decline of approximately 2.74%[178]. - The total amount of funds raised was CNY 171,599.38 million, with a net amount of CNY 166,974.02 million after deducting issuance costs[155].

[Ta健ble康_Sto元ckN（am6eR0p0tT3yp8e0] ） 公司研究/公司点评 业绩维持稳健，双轮驱动战略持续推进 投资评级：增持（维持） 主要观点： [Table_Rank] 报告日期： 2024-05-09 ⚫[ T事ab件le：_S ummary] 公司2023年实现营业收入166.46亿元，同比-2.90%；归母净利润14.43 [收Ta盘bl价e_（Ba元se）D ata] 13.03 亿元，同比-3.99%；扣非归母净利润13.74亿元，同比-3.18%。 近12个月最高/最低（元） 13.95/9.70 公司2024Q1收入为43.40亿元，同比-4.81%；归母净利润为4.40亿 总股本（百万股） 1,867 流通股本（百万股） 1,867 元，同比-4.96%；扣非归母净利润为4.28亿元，同比-4.26%。 流通股比例（%） 100.00 ⚫ 分析点评 总市值（亿元） 243 2023年：23Q4营收微降，经营现金流稳定 流通市值（亿元） 243 23Q4：单季度来看，公司2023Q4收入为39.95亿元，同比-3.28%； [公Ta司ble价_C格ha与rt]沪 深300走 ...

Investment Rating - The report maintains an "Accumulate" rating for the company [1][2] - The target price is set at 15.12 CNY, up from the previous forecast of 13.68 CNY [1][2] Core Insights - The company's performance meets expectations, with a gradual increase in the volume of the drug Tobramycin anticipated [1] - The respiratory segment is expected to show positive growth, particularly with the approval of a new product, which will contribute to revenue [1] - The report highlights the potential for Tobramycin to offset revenue declines caused by price reductions in other products [1] Financial Summary - For Q1 2024, the company reported a net profit attributable to shareholders of 1.44 billion CNY, a decrease of 4% year-on-year [1] - The revenue for Q1 2024 is projected at 4.34 billion CNY, reflecting a decline of 4.8% [1] - The earnings per share (EPS) forecast for 2024 is 0.84 CNY, with subsequent years showing an upward trend [1][2] Market Position - The total market capitalization of the company is 22.4 billion CNY [2] - The stock has a 52-week price range of 10.43 to 13.86 CNY [2] - The company operates in the pharmaceutical sector, focusing on a diverse range of products including chemical formulations and traditional Chinese medicine [2]

Financial Performance - The company's operating revenue for Q1 2024 was CNY 4,339,814,452.16, a decrease of 4.81% compared to the same period last year[4] - Net profit attributable to shareholders was CNY 439,798,106.55, down 4.96% year-on-year[4] - The revenue from chemical preparations was CNY 2,141 million, a decline of 4.86% year-on-year, with hormone products showing a growth of 39.89% to CNY 807 million[5] - The company reported a significant increase in revenue from diagnostic reagents and equipment, which rose by 60.26% to CNY 236 million[5] - The company’s basic earnings per share for Q1 2024 were CNY 0.2357, a decrease of 1.96% year-on-year[4] - The company’s weighted average return on equity decreased by 0.34 percentage points to 3.15%[4] - Total operating revenue for Q1 2024 was approximately ¥4.34 billion, a decrease of 4.8% compared to ¥4.56 billion in Q1 2023[18] - Net profit for Q1 2024 reached approximately ¥925.1 million, an increase of 5.3% from ¥878.5 million in Q1 2023[18] - Operating profit for Q1 2024 was approximately ¥1.09 billion, up from ¥1.05 billion in Q1 2023, reflecting a growth of 4.0%[18] - Total comprehensive income for Q1 2024 was approximately ¥902.6 million, compared to ¥794.8 million in Q1 2023, indicating an increase of 13.6%[19] - Basic earnings per share for Q1 2024 were ¥0.2357, slightly down from ¥0.2404 in Q1 2023[19] - The total operating costs for Q1 2024 were approximately ¥3.30 billion, down from ¥3.56 billion in Q1 2023, reflecting a decrease of 7.5%[18] Cash Flow and Assets - The net cash flow from operating activities increased significantly by 291.91% to CNY 972,276,972.65, primarily due to reduced procurement and expense expenditures[7] - Cash flow from operating activities for Q1 2024 was approximately ¥972.3 million, significantly higher than ¥248.1 million in Q1 2023[20] - Current assets totaled RMB 23,443,751,168.49, down from RMB 23,874,630,390.40 at the end of 2023, primarily due to a decrease in cash and cash equivalents[16] - The company's cash and cash equivalents decreased to RMB 15,118,198,045.39 from RMB 15,691,888,314.83, reflecting a decline of approximately 3.65%[16] - Accounts receivable increased to RMB 2,641,495,146.49 from RMB 2,692,941,866.24, indicating a slight rise in receivables[16] - Total assets at the end of Q1 2024 were CNY 36,462,147,240.89, reflecting a slight increase of 0.29% from the end of the previous year[4] - The non-current assets increased to RMB 13,018,396,072.40 from RMB 12,483,495,868.42, reflecting a growth of approximately 4.29%[16] Shareholder Information - The total number of common shareholders at the end of the reporting period was 78,332[11] - The largest shareholder, Shenzhen Baiye Yuan Investment Co., Ltd., holds 895,653,653 shares, accounting for 47.98% of the total shares[11] - The second-largest shareholder, Hong Kong Central Clearing Limited, holds 87,780,030 shares, representing 4.70%[11] - The company reported a total of 9,370,400 shares under the third phase of the long-term partner shareholding plan[12] - The shareholding structure indicates no related party relationships among the top shareholders[12] - The top 10 shareholders collectively hold a significant portion of the shares, with the largest shareholder alone holding nearly half[11] - The company has not reported any significant changes in the shareholding structure due to margin trading activities[13] - The total shares held by the China Agricultural Bank's CSI 500 ETF amounted to 10,353,414, representing 0.55% of the total shares[13] Liabilities and Equity - Total liabilities decreased to RMB 12,925,489,486.86 from RMB 13,718,595,768.18, showing a reduction of approximately 5.78%[17] - The company's equity attributable to shareholders rose to RMB 14,234,869,509.55 from RMB 13,755,901,924.06, an increase of about 3.48%[17] - Short-term borrowings decreased significantly to RMB 1,360,009,625.00 from RMB 2,076,159,347.22, a reduction of approximately 34.5%[17] - The company reported a decrease in current liabilities, totaling RMB 9,865,306,342.16 compared to RMB 9,860,687,845.52 at the end of 2023[17] - The company’s retained earnings increased to RMB 9,878,656,063.35 from RMB 9,441,857,956.80, indicating a growth of about 4.64%[17] Audit and Reporting - The report does not indicate any significant operational issues during the reporting period[15] - There were no audit opinion types applicable for the quarterly financial statements[15] - Health元药业集团将于2024年首次执行新会计准则[22] - 2024年第一季度财务报表未涉及调整[22] - 健康元药业集团于2024年4月25日发布财报[22] - 2024年第一季度报告包含12页内容[22] - 报告未提及具体业绩数据和用户数据[22] - 未来展望和业绩指引未在报告中详细说明[22] - 新产品和新技术研发的相关信息未披露[22] - 市场扩张和并购策略未在报告中提及[22] - 其他新策略的具体内容未被列出[22] - 报告未提供具体的财务指标和百分比[22]

Financial Performance - In 2023, the company achieved operating revenue of RMB 16.646 billion, a decrease of 2.90% year-on-year[15]. - The net profit attributable to shareholders was RMB 1.443 billion, down 3.99% year-on-year, while the net profit excluding non-recurring gains and losses was RMB 1.374 billion, a decline of 3.18% year-on-year[15]. - The company reported a total distributable profit of RMB 2.749 billion for the year, after accounting for various adjustments[5]. - The basic earnings per share for 2023 was ¥0.7580, representing a decrease of 4.46% from ¥0.7934 in 2022[43]. - The total assets at the end of 2023 were approximately ¥36.36 billion, an increase of 1.74% from ¥35.74 billion at the end of 2022[42]. - The net assets attributable to shareholders increased by 4.83% to approximately ¥13.76 billion at the end of 2023, compared to ¥13.12 billion at the end of 2022[42]. - The cash flow from operating activities for 2023 was approximately ¥3.93 billion, a decrease of 1.23% from ¥3.98 billion in 2022[42]. - The weighted average return on equity for 2023 was 11.00%, down 1.23 percentage points from 12.23% in 2022[43]. - The company reported a decrease in the net profit margin, indicating potential challenges in maintaining profitability[41]. Research and Development - The company has made significant progress in its R&D pipeline, with multiple innovative drugs and complex formulations advancing, including the approval of new indications for injection drugs and a COVID-19 vaccine[17]. - The company has filed for clinical trials for several new drugs, including TG-1000 capsules and a humanized monoclonal antibody injection[17]. - The company has successfully introduced new drugs such as TG-1000 and DBM-1152A, expanding its research pipeline in respiratory diseases[19]. - The company has applied for 14 national invention patents and achieved breakthroughs in synthetic biology research[19]. - The company continues to focus on innovation-driven development, enhancing its R&D capabilities through both internal development and external collaborations[19]. - The company is committed to enhancing its research and development capabilities to drive future growth[41]. - The company is focusing on high-barrier complex formulations and innovative drugs as part of its dual-driven strategy[132]. - The company is actively pursuing regulatory approvals for multiple new products to strengthen its market position[142]. - The company is leveraging its research on classic formulations to address unmet medical needs in various therapeutic areas[140]. - The company has a total of 1,740 R&D personnel, with 552 holding master's degrees or higher[133]. Market Expansion and Sales Strategy - In 2023, the group achieved overseas revenue of 2.584 billion RMB, accounting for 15.64% of the main business income[20]. - The group successfully registered 4 chemical formulations in overseas markets and submitted 14 new registration applications in 2023[21]. - The company is transitioning towards being an innovative pharmaceutical enterprise, emphasizing a dual strategy of "innovative drugs + high-barrier complex formulations" to meet unmet clinical needs[52]. - The company is focusing on expanding online sales channels, including Tmall, JD.com, and Douyin, to improve market penetration[89]. - The company is actively expanding its digital marketing platform, with over 5,000 respiratory experts and more than 25 million views on health-related live broadcasts[84]. - The company aims to enhance brand and user engagement through a brand-driven business model and digital marketing strategies, focusing on both online and offline sales channels[176]. - The company is focusing on enhancing its commercialization capabilities and integrating global resources to accelerate its transformation into an innovative pharmaceutical enterprise[78]. Corporate Governance and Compliance - The company held 1 annual general meeting and 4 extraordinary general meetings during the reporting period, ensuring fair and open decision-making for shareholders[190]. - The board of directors convened 15 meetings, with 9 directors including 4 independent directors, ensuring effective governance and decision-making[192]. - The supervisory board held 10 meetings, focusing on reviewing periodic reports and major investment matters to protect shareholder interests[194]. - The company has established a long-term mechanism to prevent the controlling shareholder from misappropriating company funds, ensuring independent operations[191]. - The company emphasizes investor relations, actively communicating with shareholders and addressing their concerns regarding business operations[196]. - The company adheres to strict information disclosure practices, ensuring timely and accurate communication with all shareholders[197]. - The company is committed to continuous improvement in corporate governance, aligning with legal regulations and enhancing internal management[198]. Social Responsibility and ESG - The group’s public welfare donations amounted to approximately 25.98 million RMB in 2023[23]. - The company emphasizes the integration of ESG principles into its strategic planning and daily operations[22]. - The company achieved a rating upgrade from "BBB" to "AA" by MSCI, reflecting its strong ESG management and sustainable development capabilities[61]. - The company is committed to green development, enhancing environmental standards and monitoring energy consumption and emissions during production[178]. - The company is actively managing raw material supply risks by selecting qualified suppliers and conducting thorough audits[184]. Challenges and Risks - The company faced challenges in prescription drug sales due to price reductions and industry regulations, prompting a comprehensive marketing system improvement[54]. - The company acknowledges R&D risks associated with high investment and regulatory challenges in new drug development[185]. - The company faces significant policy risks due to ongoing healthcare reforms and changes in drug procurement policies, which may impact sales prices and market share[179]. - The chemical preparation sector is experiencing a slowdown in revenue and profit growth due to policies like medical insurance cost control and centralized procurement[122].